Charles River Labs stock trades near TD Cowen target after recent gains
Published on 09/09/2026 at 22:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Charles River Laboratories International, Inc. stock (ISIN US1591881009) closed at 283.98 USD on the New York Stock Exchange on September 8, 2026, leaving the shares only a few dollars above the average analyst price target of 281 USD and highlighting a more limited upside in the near term.
Analyst targets frame current valuation
According to an overview on the company’s investor relations page, the median analyst price target for Charles River Labs stood at 229.21 USD based on a prior closing price of 234.12 USD as of August 4, 2026, implying a 2.10 percent downside from that earlier level and showing how consensus expectations have been comparatively cautious in recent months.Charles River Laboratories In contrast, a more optimistic view comes from TD Cowen, which raised its price target for Charles River Labs to 300 USD on August 10, 2026, positioning its forecast clearly above the average analyst target and suggesting potential upside of about 6 percent from the recent closing level of 283.98 USD.Ad-hoc-news
As that German-language report notes, Charles River Labs stock traded at 283.98 USD at 14:01 local time on September 8, 2026 on the NYSE, only a few dollars above the average analyst target of 281 USD, which underlines that the current price already discounts a good portion of expected earnings growth while still leaving room to reach TD Cowen’s 300 USD target.Ad-hoc-news For investors, the spread between the average target of 281 USD and the more ambitious 300 USD level has become a key reference for assessing the risk-reward profile in the current environment.
Earnings estimates point to solid growth
The same analyst information page on the investor relations site shows that for the quarterly period ending September 2026, the mean earnings per share estimate for Charles River Labs is 3.07 USD, with a high estimate of 3.12 USD and a low of 3.04 USD across 11 analysts, indicating a relatively tight range around expectations.Charles River Laboratories The data also show a small positive mean percentage change of 0.33 percent in estimates for that quarter, which suggests that consensus earnings expectations have edged higher rather than lower in the latest revision cycle.
For the wider investment horizon, long-term growth expectations compiled on the same page indicate that analysts see an average annual growth rate of 8.89 percent in key metrics such as earnings, with the high estimate at 9.20 percent and the low at 8.57 percent, based on two contributing estimates.Charles River Laboratories These long-term projections underpin the valuation argument that a premium multiple can be justified if the company continues to deliver mid- to high-single-digit growth in profits.
The analyst ratios section on the investor relations site further illustrates this valuation picture: for the fiscal years labeled FY0, FY1 and FY2, key valuation ratios stand at 22.77, 21.06 and 18.97 respectively, indicating that the forward-looking metrics gradually decline as earnings are expected to grow, which can be interpreted as the market pricing in some earnings expansion over the next several years.Charles River Laboratories In practical terms, that means investors are paying a higher multiple on current-year earnings, with the implied valuation easing as the forecast horizon extends, a typical pattern for a company still in a growth phase.
Price level and risk considerations
With a closing price of 283.98 USD on September 8, 2026 on the NYSE, Charles River Labs stock is currently trading roughly 2.5 percent above the average analyst target of 281 USD quoted in recent coverage, which can be seen as a sign that the market has moved ahead of the more cautious consensus.Ad-hoc-news On the other hand, the TD Cowen target of 300 USD remains about 5.7 percent above the latest closing price, leaving scope for further gains if upcoming quarterly results match or exceed the 3.07 USD EPS estimate for the quarter ending September 2026.Charles River Laboratories
A key risk factor implicit in the current setup is that any disappointment relative to those earnings expectations could lead to a compression of the valuation ratios that presently stand above 20 on a current-year basis.Charles River Laboratories With the stock already trading very near or slightly above the average target, investors may react more strongly to negative surprises than to positive ones, which makes the next quarterly report and any guidance updates particularly important in shaping the trajectory of Charles River Labs stock.
Charles River Labs stock at a glance
As of the latest completed trading day, September 8, 2026, Charles River Labs stock closed at 283.98 USD on the NYSE, with that level serving as the current reference price in the US dollar home market.Ad-hoc-news For investors tracking the stock into September 9, 2026, this closing price, the spread between the 281 USD average target and the 300 USD TD Cowen target, and the earnings expectations for the September 2026 quarter together provide the key numerical anchors for assessing whether the current valuation still leaves sufficient upside potential.
Charles River Labs stock facts
- Company: Charles River Laboratories International, Inc.
- ISIN: US1591881009
- Ticker: CRL
- Trading venue: NYSE
- Price (as of September 8, 2026, 14:01): 283.98 USD
- Market capitalization: not specified (as of September 8, 2026)
- Sector / Industry: Healthcare - Life Sciences Tools and Services
- Index membership: S&P 500
